London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Been some decent buying here last two sessions
I think anything in the Biotech space will do well at the moment. Expect to see AI profits moving towards it, synthetic biotechs is the space to be (I know they are not that) but expect to see pharma sector do well.
Trending up, extremely small float and funding sorted. Did not realise how big the peanut allergy market was.
As per RNS 7th May
Allergy Therapeutics provides further detail from positive top line results from G306 Phase III field trial to evaluate efficacy and safety of Grass MATA MPL
As previously communicated, the treatment was well tolerated with no unexpected safety signals. Further exploratory endpoint analyses (including an extensive biomarker evaluation) of the G306 trial are now underway. Full results, including secondary and exploratory endpoints, will be presented at the upcoming European Academy of Allergy & Clinical Immunology conference in June 2024 and submitted for peer-reviewed publication later this year. The Group's preparation for the marketing authorisation application (MAA) is well underway, with a planned submission in Q4 2024
Took a position today.
Patiently waiting for goods news, this will move very quickly soon.
WHERE TF is everyone??? 😁😁👍
Agree, moving in the right direction, was hoping for some small movement today.
This is under the radar at the moment, I do think it will suddenly have a large jump once we get more updates on the treatment trials. Could then be bought out by a large company for millions
Annnnd no comments? Wakey, wakey folks.
Good news imo but welcome your comments.
This will soon lift off very soon and catch people out, under the radar currently.
There are plenty of large buys
It would make a nice change for the company to provide more detail on Grass MATA MPL . In the Half year trading update is states that
The first scientific advisory meeting with regulators is anticipated to occur in late Q1 2024, where discussions will confirm the pathway forward for potential progression to the marketing authorisation application process.
The 20% drop in share price today tells you all you need to know regarding the RNS today.
Not sure what to think, just had a look at them, seem to be lots of bla bla bla, fluffy stuff . Would have liked a straightforward determination to generate improved revenues this year
Coming soon....the audited accounts!
RNS from 15 December 2023: "Allergy Therapeutics plc (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that its auditor, BDO LLP ("BDO"), has informed the Company that it requires additional time to complete its audit for the year ended 30 June 2023, due to resource availability within the audit engagement team." - It's the auditor BDO who is the reason for the delay, not Allergy Therapeutics.
Shares suspended pending publication of accounts....
Good science but crooked/incompetent managers?
What will the accounts reveal?
I disagree, the CEO is in charge of the day-to-day management of the Company in accordance with the instructions and orders given by the Board. The CEO sets the ground of the internal control environment by providing leadership and direction to senior managers and reviewing the way they are controlling the business including ensuring audits are completed within the set timeframes
I don't see how BDO's inability to complete audits on time for so many of their clients is the fault of the CEO of said clients.
I agree Manuel Llobet should go. It is extremely disappointing that this suspension had happened. Especially the recent good news regarding the successful grass trial. This was the first indication that AGY is heading in the right direction. If I was a major shareholder, he would be dismissed with immediate effect.
The blame lies with Manuel Llobet, Chief Executive Officer of the Company, once is forgiven, twice is incompetent. He needs to be dismissed and let go with minimum share options as he has failed miserably over the past 2 years
Here we go again, another share suspension until next year. Was about to increase my positon but have to wait to see what happens. Any idea anyone?
Finally some good news for share holders. Now just hope the peanut vaccine goes the same way.
I can see the share price from here to climb. Being watching this company for over two years and just starting buying in last month.
Pass ref working cash but not an issue imo, a P3 suce$$ for an effective drug to fight grass pollen allergies an easy winner. While not life threatening the market is a large one so a Big Pharma Company will buy AGY for chump change in 2024 imo.
Correct me if im wrong willy agy need more cash in jan 2024
Success! It worked as hoped.
3 very large buys late this afternoon, things are on the up. patience is key.